ArticleNature communications2026
Atroposelective interrupted CuAAC reaction using cyclic diaryliodoniums.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Copper-catalyzed enantioselective interrupted azide-alkyne cycloaddition to access axially chiral diaryl ethers.Chemical science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Copper-catalyzed azide-alkyne cycloaddition (CuAAC) is a pivotal strategy for joining two fragments, including bioactive moieties under mild conditions. In recent years, "interrupted" CuAAC reaction has emerged by intercepting copper triazolide intermediates, thereby significantly broadening the scope of these transformations. However, asymmetric transformations based on the interruption of copper triazolide intermediates have remained elusive. In this work, we present an efficient and mild approach that intercepts a copper triazolide intermediate with a cyclic diaryliodonium reagent, enabling a three-component coupling of the cyclic diaryliodonium species, an alkyne, and an azide under atroposelective control. This method constitutes an asymmetric interrupted CuAAC reaction and furnishes a diverse array of structurally unique atropisomeric biaryl triazoles. Mechanistic investigations reveal an unusual secondary kinetic isotope effect for the terminal alkyne, while in situ calorimetry-based reaction progress kinetic analysis identifies the individual reaction orders of each substrate: formal 0.4th-order for cyclic diaryliodonium and first-order for both the alkyne and the azide. The overall rate is governed by copper-mediated cyclometallation of the alkyne and azide, as well as the oxidative addition of the copper triazolide intermediate to the cyclic diaryliodonium reagent.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.